Agammaglobulinemia / / edited by Alessandro Plebani, Vassilios Lougaris |
Edizione | [1st ed. 2015.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 |
Descrizione fisica | 1 online resource (126 p.) |
Disciplina | 616.0798 |
Collana | Rare Diseases of the Immune System |
Soggetto topico |
Immunology
Rheumatology Hematology Pediatrics Cell biology Cell Biology |
ISBN | 3-319-22714-9 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Early B Cell Biology -- Agammaglobulinemia: Basic Pathogenesis and Clinical Spectrum (Including X-Linked and Autosomal Recessive Forms) -- Pulmonary Complications in Agammaglobulinemia -- Immunoglobulin Replacement Therapy: Past, Present, Future -- Mutational Spectrum of BTK: A Comprehensive Description -- Novel Therapeutic Options for X-Linked Agammaglobulinemia -- BTK in Non B Cells. |
Record Nr. | UNINA-9910300177003321 |
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Antibodies for infectious diseases / / edited by James E. Crowe, Jr., Diana Boraschi and Rino Rappuoli |
Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , 2015 |
Descrizione fisica | 1 online resource (476 p.) |
Disciplina | 616.0798 |
Soggetto topico |
Immunoglobulins
Communicable diseases - Immunological aspects |
ISBN |
1-68367-340-9
1-68367-098-1 1-55581-741-6 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Cover ""; ""Half Title ""; ""Title Page ""; ""Copyright ""; ""Contents ""; ""Contr ibutors ""; ""Preface ""; ""INTRODUCTION""; ""Chapter 1: History and Practice: Antibodies in Infectious Diseases""; ""HISTORICAL PERSPECTIVE""; ""INTRODUCTION TO ANTIBODIES""; ""METHODS AND PLATFORMS FOR GENERATING ANTIBODIES""; ""STRATEGIC CONSIDERATIONS IN DEVELOPING ANTIBODY-BASED THERAPIES FOR INFECTIOUS DISEASES""; ""EXAMPLES OF ANTIBODIES THAT ARE OR WERE IN DEVELOPMENT FOR INFECTIOUS DISEASES""; ""FUTURE PERSPECTIVES FOR ANTIBODY TREATMENTS IN INFECTIOUS DISEASES""; ""ACKNOWLEDGMENT""; ""CITATION""
""REFERENCES""""GENERAL FEATURES OF IMMUNOGLOBULINS""; ""Chapter 2: Functions of Antibodies""; ""INTRODUCTION""; ""ANTIBODY FUNCTIONS INDEPENDENT OF EFFECTOR CELLS OR EFFECTOR MOLECULES""; ""INHIBITION OF LATER STEPS""; ""ANTIBODY FUNCTIONS DEPENDENT ON COMPLEMENT""; ""ANTIBODY FUNCTIONS DEPENDENT ON Fc-Fc RECEPTOR INTERACTIONS""; ""OTHER ANTIBODY FUNCTIONS""; ""CONCLUSIONS""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES""; ""Chapter 3: Antibody Structure""; ""BASICS OF ANTIBODY STRUCTURE""; ""CDR H3: SIZE AND SUBTERFUGE""; ""HEAVY CHAIN DOMINATION AND FRAMEWORK CONTACTS"" ""DISULFIDES IN THE CDRs""""SELF-CARBOHYDRATE RECOGNITION: PENETRATING THE GLYCAN SHIELD""; ""UNUSUAL INDELS""; ""MECHANISMS OF ANTIBODY NEUTRALIZATION""; ""SUMMARY""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 4: The Role of Complement in Antibody Therapy for Infectious Diseases""; ""INTRODUCTION""; ""COMPLEMENT ACTIVATION""; ""Ab-MEDIATED COMPLEMENT ACTIVATION""; ""EFFECTOR RESPONSES AND THEIR ROLE IN MAb TREATMENTS""; ""MANIPULATING Ab-MEDIATED COMPLEMENT RESPONSES""; ""COMPLEMENT EVASIVE PROPERTIES OF PATHOGENS""; ""CONCLUSIONS AND FUTURE PERSPECTIVE"" ""ACKNOWLEDGMENTS""""CITATION""; ""REFERENCES""; ""Chapter 5: Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment""; ""IMMUNOLOGICAL MECHANISMS OF ALLERGIC DISEASES AND THE ROLE OF IgE ANTIBODIES""; ""IgE ANTIBODIES IN INFECTIOUS DISEASES""; ""ANTIBODIES IN THE TREATMENT OF ALLERGIES""; ""THE OPPOSITE SIDE OF THE COIN: HARNESSING THE ALLERGIC RESPONSE AGAINST CANCER AND THE EMERGENCE OF ANTIBODIES OF THE IgE CLASS FOR CANCER THERAPY""; ""CONCLUDING REMARKS AND FUTURE ROLES OF ANTIBODIES IN THERAPY""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES"" ""ANTIBODY DISCOVERY APPROACHES""""Chapter 6: Phage and Yeast Display""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING PHAGE DISPLAY TECHNOLOGY""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING YEAST DISPLAY TECHNOLOGY""; ""CONCLUSIONS""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 7: Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells""; ""MANY WAYS TO MAKE HUMAN MONOCLONAL ANTIBODIES""; ""EFFICIENT IMMORTALIZATION OF MEMORY B CELLS BY USING EBV AND CpG"" ""LONG-TERM CULTURE OF SINGLE PLASMA CELLS AND THEIR INTERROGATION USING MULTIPLE ASSAYS"" |
Record Nr. | UNINA-9910555131903321 |
Washington, District of Columbia : , : ASM Press, , 2015 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Antibodies for infectious diseases / / edited by James E. Crowe, Jr., Diana Boraschi and Rino Rappuoli |
Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , 2015 |
Descrizione fisica | 1 online resource (476 p.) |
Disciplina | 616.0798 |
Soggetto topico |
Immunoglobulins
Communicable diseases - Immunological aspects |
ISBN |
1-68367-340-9
1-68367-098-1 1-55581-741-6 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Cover ""; ""Half Title ""; ""Title Page ""; ""Copyright ""; ""Contents ""; ""Contr ibutors ""; ""Preface ""; ""INTRODUCTION""; ""Chapter 1: History and Practice: Antibodies in Infectious Diseases""; ""HISTORICAL PERSPECTIVE""; ""INTRODUCTION TO ANTIBODIES""; ""METHODS AND PLATFORMS FOR GENERATING ANTIBODIES""; ""STRATEGIC CONSIDERATIONS IN DEVELOPING ANTIBODY-BASED THERAPIES FOR INFECTIOUS DISEASES""; ""EXAMPLES OF ANTIBODIES THAT ARE OR WERE IN DEVELOPMENT FOR INFECTIOUS DISEASES""; ""FUTURE PERSPECTIVES FOR ANTIBODY TREATMENTS IN INFECTIOUS DISEASES""; ""ACKNOWLEDGMENT""; ""CITATION""
""REFERENCES""""GENERAL FEATURES OF IMMUNOGLOBULINS""; ""Chapter 2: Functions of Antibodies""; ""INTRODUCTION""; ""ANTIBODY FUNCTIONS INDEPENDENT OF EFFECTOR CELLS OR EFFECTOR MOLECULES""; ""INHIBITION OF LATER STEPS""; ""ANTIBODY FUNCTIONS DEPENDENT ON COMPLEMENT""; ""ANTIBODY FUNCTIONS DEPENDENT ON Fc-Fc RECEPTOR INTERACTIONS""; ""OTHER ANTIBODY FUNCTIONS""; ""CONCLUSIONS""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES""; ""Chapter 3: Antibody Structure""; ""BASICS OF ANTIBODY STRUCTURE""; ""CDR H3: SIZE AND SUBTERFUGE""; ""HEAVY CHAIN DOMINATION AND FRAMEWORK CONTACTS"" ""DISULFIDES IN THE CDRs""""SELF-CARBOHYDRATE RECOGNITION: PENETRATING THE GLYCAN SHIELD""; ""UNUSUAL INDELS""; ""MECHANISMS OF ANTIBODY NEUTRALIZATION""; ""SUMMARY""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 4: The Role of Complement in Antibody Therapy for Infectious Diseases""; ""INTRODUCTION""; ""COMPLEMENT ACTIVATION""; ""Ab-MEDIATED COMPLEMENT ACTIVATION""; ""EFFECTOR RESPONSES AND THEIR ROLE IN MAb TREATMENTS""; ""MANIPULATING Ab-MEDIATED COMPLEMENT RESPONSES""; ""COMPLEMENT EVASIVE PROPERTIES OF PATHOGENS""; ""CONCLUSIONS AND FUTURE PERSPECTIVE"" ""ACKNOWLEDGMENTS""""CITATION""; ""REFERENCES""; ""Chapter 5: Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment""; ""IMMUNOLOGICAL MECHANISMS OF ALLERGIC DISEASES AND THE ROLE OF IgE ANTIBODIES""; ""IgE ANTIBODIES IN INFECTIOUS DISEASES""; ""ANTIBODIES IN THE TREATMENT OF ALLERGIES""; ""THE OPPOSITE SIDE OF THE COIN: HARNESSING THE ALLERGIC RESPONSE AGAINST CANCER AND THE EMERGENCE OF ANTIBODIES OF THE IgE CLASS FOR CANCER THERAPY""; ""CONCLUDING REMARKS AND FUTURE ROLES OF ANTIBODIES IN THERAPY""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES"" ""ANTIBODY DISCOVERY APPROACHES""""Chapter 6: Phage and Yeast Display""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING PHAGE DISPLAY TECHNOLOGY""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING YEAST DISPLAY TECHNOLOGY""; ""CONCLUSIONS""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 7: Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells""; ""MANY WAYS TO MAKE HUMAN MONOCLONAL ANTIBODIES""; ""EFFICIENT IMMORTALIZATION OF MEMORY B CELLS BY USING EBV AND CpG"" ""LONG-TERM CULTURE OF SINGLE PLASMA CELLS AND THEIR INTERROGATION USING MULTIPLE ASSAYS"" |
Record Nr. | UNINA-9910830911403321 |
Washington, District of Columbia : , : ASM Press, , 2015 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Antibody engineering / / edited by Thomas Böldicke |
Pubbl/distr/stampa | Rijeka, Croatia : , : IntechOpen, , [2018] |
Descrizione fisica | 1 online resource (312 pages) |
Disciplina | 616.0798 |
Soggetto topico | Immunoglobulins |
ISBN |
953-51-3975-4
953-51-3826-X |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910265149703321 |
Rijeka, Croatia : , : IntechOpen, , [2018] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
B Cell Receptor Signaling / / edited by Tomohiro Kurosaki, Jürgen Wienands |
Edizione | [1st ed. 2016.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 |
Descrizione fisica | 1 online resource (231 p.) |
Disciplina | 616.0798 |
Collana | Current Topics in Microbiology and Immunology |
Soggetto topico |
Immunology
Medicine - Research Biology - Research Cancer Biomedical Research Cancer Biology |
ISBN | 3-319-26133-9 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Assembly and function of the precursor B-cell receptor -- Receptor Dissociation and B cell activation -- Molecular mechanisms of B cell antigen gathering and endocytosis -- BTK signaling in B cell differentiation and autoimmunity -- The memory function of the B cell antigen receptor -- PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL) -- Role of Calcium Signaling in B Cell Activation and Biolog -- Roles of the NF-kappaB pathway in B-lymphocyte biology -- MAP kinase cascades in antigen receptor signaling and physiology. |
Record Nr. | UNINA-9910253880103321 |
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
B Cells in Immunity and Tolerance / / edited by Ji-Yang Wang |
Edizione | [1st ed. 2020.] |
Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
Descrizione fisica | 1 online resource (190 pages) |
Disciplina | 616.0798 |
Collana | Advances in Experimental Medicine and Biology |
Soggetto topico |
Immunology
Molecular biology Allergy Molecular Medicine Allergology Cèl·lules B Immunologia Biologia molecular |
Soggetto genere / forma | Llibres electrònics |
ISBN | 981-15-3532-9 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | B cell development and maturation -- B cell receptor signalling -- Involvement of reactive oxygen species (ROS) in BCR signaling as a second messenger -- Germinal center reaction -- Memory B cells in local and systemic sites -- Regulation of plasma cell differentiation -- Regulation of humoral immune responses and B cell tolerance by the IgM Fc receptor -- Regulatory B cells -- Diversified IgA-bacteria interaction in gut homeostasis -- Primary antibody deficiencies -- B cell-mediated autoimmune diseases -- B cell lymphomas. |
Record Nr. | UNINA-9910409697303321 |
Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Catalytic antibodies [[electronic resource] /] / edited by Ehud Keinan |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
Descrizione fisica | 1 online resource (618 p.) |
Disciplina |
571.967
616.0798 |
Altri autori (Persone) | KeinanEhud |
Soggetto topico |
Monoclonal antibodies
Antibody-enzyme conjugates |
Soggetto genere / forma | Electronic books. |
ISBN |
1-280-52020-5
9786610520206 3-527-60366-2 3-527-60505-3 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Catalytic Antibodies; Foreword; Table of Contents; Preface; List of Contributors; 1 Immunological Evolution of Catalysis; 1.1 Introduction; 1.2 Parallels between Antibody and Enzyme Evolution; 1.3 Evolution of Catalytic Antibodies; 1.4 Ferrochelatase Antibody 7G12 - Evolution of the Strain Mechanism; 1.5 Esterase Antibody 48G7 - Effect of Distant Mutations on Catalysis; 1.6 Sulfur Oxidase Antibody 28B4 - Incremental Changes in Evolution; 1.7 Oxy-Cope Antibody AZ28 - Evolution of Conformational Diversity in Catalysis
1.8 Diels-Alderase Antibody 39A11 - Evolution of a Polyspecific Antibody combining Site1.9 Conclusions; References; 2 Critical Analysis of Antibody Catalysis; 2.1 Introduction; 2.2 Exploiting Antibodies as Catalysts; 2.3 Catalytic Efficiency; 2.4 Hapten Design; 2.5 Representative Catalytic Antibodies; 2.5.1 Proximity Effects; 2.5.1.1 Sigmatropic Rearrangements; 2.5.1.2 Cycloadditions; 2.5.2 Strain; 2.5.2.1 Ferrochelatase Mimics; 2.5.2.2 Other Systems; 2.5.3 Electrostatic Catalysis; 2.5.3.1 Acyl Transfer Reactions; 2.5.4 Functional Groups; 2.5.4.1 Aldolases; 2.6 Perspectives 2.6.1 General Lessons from Comparisons of Enzymes and Antibodies2.6.2 How efficient does catalysis need to be?; 2.6.3 Strategies for Optimizing Efficiency; 2.6.3.1 Better Haptens; 2.6.3.2 Screening; 2.6.3.3 Engineering; 2.6.3.4 Selection; 2.6.3.5 Other Scaffolds; 2.7 Conclusions; References; 3 Theoretical Studies of Antibody Catalysis; 3.1 Introduction; 3.2 Questions Subject to Theoretical Elucidation; 3.2.1 Predicting Antibody Structure from Sequence; 3.2.2 Predicting Binding Modes and Binding Energies; 3.2.3 Understanding Antibody Catalysis [14]; 3.2.4 General Considerations 3.3 Hydrolytic Antibodies3.3.1 Gas and Solution Phase Hydrolysis of Aryl Esters; 3.3.2 Hapten Fidelity; 3.3.3 Theoretical Exploration of Antibody Catalysis; 3.3.3.1 16G3; 3.3.3.2 6D9; 3.3.3.3 43C9; 3.3.3.4 CNJ206; 3.3.3.5 48G7; 3.3.3.6 17E8 and 29G11; 3.4 Cationic Cyclizations; 3.4.1 Antibody Catalysis of Solvolysis; 3.4.2 Antibody-Catalyzed Hydroxyepoxide Cyclization; 3.5 Antibody-Catalyzed Diels-Alder and retro-Diels-Alder Reactions; 3.5.1 The Most Efficient endo-Diels-Alderase 1E9; 3.5.2 endo-Diels-Alderase 39A11 and its Germline Precursor; 3.5.3 exo-Diels-Alderase 13G5 3.5.4 retro-Diels-Alderase 10F113.6 Other Antibody-Catalyzed Pericyclic Reactions; 3.6.1 Oxy-Cope Rearrangement Catalyzed by Antibody AZ-28; 3.6.2 1,3-Dipolar Cycloaddition Catalyzed by Antibody 29G12; 3.6.3 Chorismate-Prephenate Claisen Rearrangement Catalyzed by Antibody 1F7; 3.7 Antibody-Catalyzed Carboxybenzisoxazole Decarboxylation; 3.8 Summary; References; 4 The Enterprise of Catalytic Antibodies: A Historical Perspective; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.3.1 The Conceptual Origins of Catalytic Antibodies; 4.3.2 Tapping the Immune System for Catalysts; 4.4 Conclusions References |
Record Nr. | UNINA-9910143966603321 |
Weinheim, : Wiley-VCH | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Catalytic antibodies [[electronic resource] /] / edited by Ehud Keinan |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
Descrizione fisica | 1 online resource (618 p.) |
Disciplina |
571.967
616.0798 |
Altri autori (Persone) | KeinanEhud |
Soggetto topico |
Monoclonal antibodies
Antibody-enzyme conjugates |
ISBN |
1-280-52020-5
9786610520206 3-527-60366-2 3-527-60505-3 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Catalytic Antibodies; Foreword; Table of Contents; Preface; List of Contributors; 1 Immunological Evolution of Catalysis; 1.1 Introduction; 1.2 Parallels between Antibody and Enzyme Evolution; 1.3 Evolution of Catalytic Antibodies; 1.4 Ferrochelatase Antibody 7G12 - Evolution of the Strain Mechanism; 1.5 Esterase Antibody 48G7 - Effect of Distant Mutations on Catalysis; 1.6 Sulfur Oxidase Antibody 28B4 - Incremental Changes in Evolution; 1.7 Oxy-Cope Antibody AZ28 - Evolution of Conformational Diversity in Catalysis
1.8 Diels-Alderase Antibody 39A11 - Evolution of a Polyspecific Antibody combining Site1.9 Conclusions; References; 2 Critical Analysis of Antibody Catalysis; 2.1 Introduction; 2.2 Exploiting Antibodies as Catalysts; 2.3 Catalytic Efficiency; 2.4 Hapten Design; 2.5 Representative Catalytic Antibodies; 2.5.1 Proximity Effects; 2.5.1.1 Sigmatropic Rearrangements; 2.5.1.2 Cycloadditions; 2.5.2 Strain; 2.5.2.1 Ferrochelatase Mimics; 2.5.2.2 Other Systems; 2.5.3 Electrostatic Catalysis; 2.5.3.1 Acyl Transfer Reactions; 2.5.4 Functional Groups; 2.5.4.1 Aldolases; 2.6 Perspectives 2.6.1 General Lessons from Comparisons of Enzymes and Antibodies2.6.2 How efficient does catalysis need to be?; 2.6.3 Strategies for Optimizing Efficiency; 2.6.3.1 Better Haptens; 2.6.3.2 Screening; 2.6.3.3 Engineering; 2.6.3.4 Selection; 2.6.3.5 Other Scaffolds; 2.7 Conclusions; References; 3 Theoretical Studies of Antibody Catalysis; 3.1 Introduction; 3.2 Questions Subject to Theoretical Elucidation; 3.2.1 Predicting Antibody Structure from Sequence; 3.2.2 Predicting Binding Modes and Binding Energies; 3.2.3 Understanding Antibody Catalysis [14]; 3.2.4 General Considerations 3.3 Hydrolytic Antibodies3.3.1 Gas and Solution Phase Hydrolysis of Aryl Esters; 3.3.2 Hapten Fidelity; 3.3.3 Theoretical Exploration of Antibody Catalysis; 3.3.3.1 16G3; 3.3.3.2 6D9; 3.3.3.3 43C9; 3.3.3.4 CNJ206; 3.3.3.5 48G7; 3.3.3.6 17E8 and 29G11; 3.4 Cationic Cyclizations; 3.4.1 Antibody Catalysis of Solvolysis; 3.4.2 Antibody-Catalyzed Hydroxyepoxide Cyclization; 3.5 Antibody-Catalyzed Diels-Alder and retro-Diels-Alder Reactions; 3.5.1 The Most Efficient endo-Diels-Alderase 1E9; 3.5.2 endo-Diels-Alderase 39A11 and its Germline Precursor; 3.5.3 exo-Diels-Alderase 13G5 3.5.4 retro-Diels-Alderase 10F113.6 Other Antibody-Catalyzed Pericyclic Reactions; 3.6.1 Oxy-Cope Rearrangement Catalyzed by Antibody AZ-28; 3.6.2 1,3-Dipolar Cycloaddition Catalyzed by Antibody 29G12; 3.6.3 Chorismate-Prephenate Claisen Rearrangement Catalyzed by Antibody 1F7; 3.7 Antibody-Catalyzed Carboxybenzisoxazole Decarboxylation; 3.8 Summary; References; 4 The Enterprise of Catalytic Antibodies: A Historical Perspective; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.3.1 The Conceptual Origins of Catalytic Antibodies; 4.3.2 Tapping the Immune System for Catalysts; 4.4 Conclusions References |
Record Nr. | UNINA-9910829843303321 |
Weinheim, : Wiley-VCH | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Catalytic antibodies / / edited by Ehud Keinan |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
Descrizione fisica | 1 online resource (618 p.) |
Disciplina |
571.967
616.0798 |
Altri autori (Persone) | KeinanEhud |
Soggetto topico |
Monoclonal antibodies
Antibody-enzyme conjugates |
ISBN |
1-280-52020-5
9786610520206 3-527-60366-2 3-527-60505-3 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Catalytic Antibodies; Foreword; Table of Contents; Preface; List of Contributors; 1 Immunological Evolution of Catalysis; 1.1 Introduction; 1.2 Parallels between Antibody and Enzyme Evolution; 1.3 Evolution of Catalytic Antibodies; 1.4 Ferrochelatase Antibody 7G12 - Evolution of the Strain Mechanism; 1.5 Esterase Antibody 48G7 - Effect of Distant Mutations on Catalysis; 1.6 Sulfur Oxidase Antibody 28B4 - Incremental Changes in Evolution; 1.7 Oxy-Cope Antibody AZ28 - Evolution of Conformational Diversity in Catalysis
1.8 Diels-Alderase Antibody 39A11 - Evolution of a Polyspecific Antibody combining Site1.9 Conclusions; References; 2 Critical Analysis of Antibody Catalysis; 2.1 Introduction; 2.2 Exploiting Antibodies as Catalysts; 2.3 Catalytic Efficiency; 2.4 Hapten Design; 2.5 Representative Catalytic Antibodies; 2.5.1 Proximity Effects; 2.5.1.1 Sigmatropic Rearrangements; 2.5.1.2 Cycloadditions; 2.5.2 Strain; 2.5.2.1 Ferrochelatase Mimics; 2.5.2.2 Other Systems; 2.5.3 Electrostatic Catalysis; 2.5.3.1 Acyl Transfer Reactions; 2.5.4 Functional Groups; 2.5.4.1 Aldolases; 2.6 Perspectives 2.6.1 General Lessons from Comparisons of Enzymes and Antibodies2.6.2 How efficient does catalysis need to be?; 2.6.3 Strategies for Optimizing Efficiency; 2.6.3.1 Better Haptens; 2.6.3.2 Screening; 2.6.3.3 Engineering; 2.6.3.4 Selection; 2.6.3.5 Other Scaffolds; 2.7 Conclusions; References; 3 Theoretical Studies of Antibody Catalysis; 3.1 Introduction; 3.2 Questions Subject to Theoretical Elucidation; 3.2.1 Predicting Antibody Structure from Sequence; 3.2.2 Predicting Binding Modes and Binding Energies; 3.2.3 Understanding Antibody Catalysis [14]; 3.2.4 General Considerations 3.3 Hydrolytic Antibodies3.3.1 Gas and Solution Phase Hydrolysis of Aryl Esters; 3.3.2 Hapten Fidelity; 3.3.3 Theoretical Exploration of Antibody Catalysis; 3.3.3.1 16G3; 3.3.3.2 6D9; 3.3.3.3 43C9; 3.3.3.4 CNJ206; 3.3.3.5 48G7; 3.3.3.6 17E8 and 29G11; 3.4 Cationic Cyclizations; 3.4.1 Antibody Catalysis of Solvolysis; 3.4.2 Antibody-Catalyzed Hydroxyepoxide Cyclization; 3.5 Antibody-Catalyzed Diels-Alder and retro-Diels-Alder Reactions; 3.5.1 The Most Efficient endo-Diels-Alderase 1E9; 3.5.2 endo-Diels-Alderase 39A11 and its Germline Precursor; 3.5.3 exo-Diels-Alderase 13G5 3.5.4 retro-Diels-Alderase 10F113.6 Other Antibody-Catalyzed Pericyclic Reactions; 3.6.1 Oxy-Cope Rearrangement Catalyzed by Antibody AZ-28; 3.6.2 1,3-Dipolar Cycloaddition Catalyzed by Antibody 29G12; 3.6.3 Chorismate-Prephenate Claisen Rearrangement Catalyzed by Antibody 1F7; 3.7 Antibody-Catalyzed Carboxybenzisoxazole Decarboxylation; 3.8 Summary; References; 4 The Enterprise of Catalytic Antibodies: A Historical Perspective; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.3.1 The Conceptual Origins of Catalytic Antibodies; 4.3.2 Tapping the Immune System for Catalysts; 4.4 Conclusions References |
Record Nr. | UNINA-9910876996603321 |
Weinheim, : Wiley-VCH | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Decoding the Antibody Repertoire : High Throughput Sequencing of Multiple Transcripts from Single B Cells / / by Brandon DeKosky |
Autore | DeKosky Brandon |
Edizione | [1st ed. 2017.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 |
Descrizione fisica | 1 online resource (XXVIII, 87 p. 34 illus.) |
Disciplina | 616.0798 |
Collana | Springer Theses, Recognizing Outstanding Ph.D. Research |
Soggetto topico |
Antibodies
Genetic engineering Human genetics Cell biology Biochemistry Genetic Engineering Human Genetics Cell Biology Biochemistry, general |
ISBN | 3-319-58518-5 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Background -- High-throughput Sequencing of the Paired Human Immunoglobulin Heavy and Light Chain Repertoire -- In-Depth Determination and Analysis of the Human Paired Heavy and Light Chain Antibody Repertoire -- Paired VH:VL Analysis of Naïve B Cell Repertoires and Comparison to Antigen-Experienced B Cell Repertoires in Healthy Human Donors -- Conclusions and Future Perspectives -- Appendices. |
Record Nr. | UNINA-9910253930203321 |
DeKosky Brandon | ||
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|